Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis

Licenses Nanobody M6495 To Swiss Firm

Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.  

Osteoarthritis
Reversing Osteoarthritis Changes Has Proven Difficult • Source: Shutterstock

The increasing focus of big pharma companies on specific therapeutic categories can leave promising candidates in out-of-favour conditions out in the cold, but Merck KGaA has tackled the issue head on by licensing a potentially disease-modifying osteoarthritis program to Novartis AG, in a deal valued at €450m ($527m). 

Merck KGaA has out-licensed M6495, a Phase II-ready anti-ADAMTS5 Nanobody, to Novartis for an upfront payment of €50m. The Darmstadt,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.